Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Lots of Movement in Gut and Parkinson's Research.

Mercado G, Brundin P.

Trends Endocrinol Metab. 2019 Aug 28. pii: S1043-2760(19)30157-2. doi: 10.1016/j.tem.2019.08.001. [Epub ahead of print]

PMID:
31473011
2.

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.

George S, Rey NL, Tyson T, Esquibel C, Meyerdirk L, Schulz E, Pierce S, Burmeister AR, Madaj Z, Steiner JA, Escobar Galvis ML, Brundin L, Brundin P.

Mol Neurodegener. 2019 Aug 16;14(1):34. doi: 10.1186/s13024-019-0335-3.

3.

Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.

Chatterjee D, Sanchez DS, Quansah E, Rey NL, George S, Becker K, Madaj Z, Steiner JA, Ma J, Escobar Galvis ML, Kordower JH, Brundin P.

J Parkinsons Dis. 2019;9(2):315-326. doi: 10.3233/JPD-191590.

4.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.

PMID:
30745444
5.

Genetically engineered stem cell-derived neurons can be rendered resistant to alpha-synuclein aggregate pathology.

Brundin P, Coetzee GA.

Eur J Neurosci. 2019 Feb;49(3):316-319. doi: 10.1111/ejn.14333. Epub 2019 Jan 20. No abstract available.

PMID:
30614081
6.

The Times They Are a-Changin': Parkinson's Disease 20 Years from Now.

Brundin P, Bloem BR.

J Parkinsons Dis. 2018;8(s1):S1-S2. doi: 10.3233/JPD-189002. No abstract available.

7.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; and The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

8.

Cancer enzyme affects Parkinson's disease.

Brundin P, Wyse R.

Science. 2018 Nov 2;362(6414):521-522. doi: 10.1126/science.aav3986. No abstract available.

PMID:
30385560
9.

Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson's Disease.

Graham SF, Rey NL, Ugur Z, Yilmaz A, Sherman E, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P.

Metabolites. 2018 Oct 31;8(4). pii: E71. doi: 10.3390/metabo8040071.

10.

New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Shihabuddin LS, Brundin P, Greenamyre JT, Stephenson D, Sardi SP.

J Neurosci. 2018 Oct 31;38(44):9375-9382. doi: 10.1523/JNEUROSCI.1666-18.2018.

11.

The vermiform appendix impacts the risk of developing Parkinson's disease.

Killinger BA, Madaj Z, Sikora JW, Rey N, Haas AJ, Vepa Y, Lindqvist D, Chen H, Thomas PM, Brundin P, Brundin L, Labrie V.

Sci Transl Med. 2018 Oct 31;10(465). pii: eaar5280. doi: 10.1126/scitranslmed.aar5280.

PMID:
30381408
12.

Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.

Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P.

Trends Neurosci. 2019 Jan;42(1):4-13. doi: 10.1016/j.tins.2018.09.007. Epub 2018 Oct 17. Review.

13.

The Linked Clinical Trials initiative (LCT) for Parkinson's disease.

Brundin P, Wyse RK.

Eur J Neurosci. 2019 Feb;49(3):307-315. doi: 10.1111/ejn.14175. Epub 2018 Oct 28.

PMID:
30269406
14.

Parkinson Matters.

Darweesh SKL, Raphael KG, Brundin P, Matthews H, Wyse RK, Chen H, Bloem BR.

J Parkinsons Dis. 2018;8(4):495-498. doi: 10.3233/JPD-181374.

15.

Fire prevention in the Parkinson's disease brain.

Brundin L, Bergkvist L, Brundin P.

Nat Med. 2018 Jul;24(7):900-902. doi: 10.1038/s41591-018-0109-4. No abstract available.

PMID:
29988138
16.

Prion-like propagation of pathology in Parkinson disease.

Volpicelli-Daley L, Brundin P.

Handb Clin Neurol. 2018;153:321-335. doi: 10.1016/B978-0-444-63945-5.00017-9. Review.

17.

Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration.

Quansah E, Peelaerts W, Langston JW, Simon DK, Colca J, Brundin P.

Mol Neurodegener. 2018 May 24;13(1):28. doi: 10.1186/s13024-018-0260-x. Review.

18.

Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles.

Graham SF, Rey NL, Yilmaz A, Kumar P, Madaj Z, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P.

J Proteome Res. 2018 Jul 6;17(7):2460-2469. doi: 10.1021/acs.jproteome.8b00224. Epub 2018 May 25.

19.

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.

Sardi SP, Cedarbaum JM, Brundin P.

Mov Disord. 2018 May;33(5):684-696. doi: 10.1002/mds.27414. Epub 2018 Apr 27. Review.

20.

The concept of alpha-synuclein as a prion-like protein: ten years after.

Steiner JA, Quansah E, Brundin P.

Cell Tissue Res. 2018 Jul;373(1):161-173. doi: 10.1007/s00441-018-2814-1. Epub 2018 Feb 26. Review.

21.

Editorial: Pathogenic templating proteins in Neurodegenerative Disease.

Volpicelli-Daley L, Brundin P.

Neurobiol Dis. 2018 Jan;109(Pt B):175-177. doi: 10.1016/j.nbd.2017.11.004. No abstract available.

22.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

23.

Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.

Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ, Lee VM, Brundin P.

Acta Neuropathol. 2018 Jan;135(1):65-83. doi: 10.1007/s00401-017-1792-9. Epub 2017 Dec 5.

24.

Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease?

Thirtamara-Rajamani K, Li P, Escobar Galvis ML, Labrie V, Brundin P, Brundin L.

J Parkinsons Dis. 2017;7(4):577-587. doi: 10.3233/JPD-171240. Review.

25.

Prying into the Prion Hypothesis for Parkinson's Disease.

Brundin P, Melki R.

J Neurosci. 2017 Oct 11;37(41):9808-9818. doi: 10.1523/JNEUROSCI.1788-16.2017. Review.

26.

Therapeutic approaches to target alpha-synuclein pathology.

Brundin P, Dave KD, Kordower JH.

Exp Neurol. 2017 Dec;298(Pt B):225-235. doi: 10.1016/j.expneurol.2017.10.003. Epub 2017 Oct 4. Review.

27.

Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.

Labrie V, Brundin P.

J Innate Immun. 2017;9(5):437-440. doi: 10.1159/000479653. Epub 2017 Sep 2.

28.

Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein.

Tyson T, Senchuk M, Cooper JF, George S, Van Raamsdonk JM, Brundin P.

Sci Rep. 2017 Aug 8;7(1):7506. doi: 10.1038/s41598-017-07383-6.

29.

Is Exenatide a Treatment for Parkinson's Disease?

Athauda D, Wyse R, Brundin P, Foltynie T.

J Parkinsons Dis. 2017;7(3):451-458. doi: 10.3233/JPD-171192.

PMID:
28777758
30.

Axonal transport dysfunction in neurodegenerative diseases: the "holy grail" for developing disease modifying therapies?

Lamberts JT, Brundin P.

Neurobiol Dis. 2017 Sep;105:271-272. doi: 10.1016/j.nbd.2017.06.018. No abstract available.

PMID:
28734388
31.

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K.

Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. Review.

32.

Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.

Ventorp F, Bay-Richter C, Nagendra AS, Janelidze S, Matsson VS, Lipton J, Nordström U, Westrin Å, Brundin P, Brundin L.

J Parkinsons Dis. 2017;7(2):263-273. doi: 10.3233/JPD-171068.

33.

Parkinson disease.

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE.

Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.

PMID:
28332488
34.

Solving the conundrum of insoluble protein aggregates.

George S, Brundin P.

Lancet Neurol. 2017 Apr;16(4):258-259. doi: 10.1016/S1474-4422(17)30045-5. Epub 2017 Feb 24. No abstract available.

PMID:
28238710
35.

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE.

Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24. Review.

36.

Precision medicine for disease modification in Parkinson disease.

Espay AJ, Brundin P, Lang AE.

Nat Rev Neurol. 2017 Feb;13(2):119-126. doi: 10.1038/nrneurol.2016.196. Epub 2017 Jan 20. Review. No abstract available.

PMID:
28106064
37.

Oxidative stress in neurodegenerative disease: causation or association?

Van Raamsdonk JM, Vega IE, Brundin P.

Oncotarget. 2017 Feb 14;8(7):10777-10778. doi: 10.18632/oncotarget.14650. No abstract available.

38.

The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases.

Rey NL, Wesson DW, Brundin P.

Neurobiol Dis. 2018 Jan;109(Pt B):226-248. doi: 10.1016/j.nbd.2016.12.013. Epub 2016 Dec 20.

39.

Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.

Ghosh A, Tyson T, George S, Hildebrandt EN, Steiner JA, Madaj Z, Schulz E, Machiela E, McDonald WG, Escobar Galvis ML, Kordower JH, Van Raamsdonk JM, Colca JR, Brundin P.

Sci Transl Med. 2016 Dec 7;8(368):368ra174.

PMID:
27928028
40.

Mechanisms for cell-to-cell propagation no longer lag behind.

Kordower JH, Brundin P.

Mov Disord. 2016 Dec;31(12):1798-1799. doi: 10.1002/mds.26879. Epub 2016 Nov 22. No abstract available.

PMID:
27873365
41.

Is Axonal Degeneration a Key Early Event in Parkinson's Disease?

Kurowska Z, Kordower JH, Stoessl AJ, Burke RE, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S.

J Parkinsons Dis. 2016 Oct 19;6(4):703-707. Review.

PMID:
27497486
42.

Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson's Disease.

Kurowska Z, Jewett M, Brattås PL, Jimenez-Ferrer I, Kenéz X, Björklund T, Nordström U, Brundin P, Swanberg M.

Sci Rep. 2016 Aug 23;6:31701. doi: 10.1038/srep31701.

43.

Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease.

Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P.

J Exp Med. 2016 Aug 22;213(9):1759-78. doi: 10.1084/jem.20160368. Epub 2016 Aug 8.

44.

An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation.

Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landén M, Samuelsson M, Lundgren K, Brundin P, Fuchs D, Postolache TT, Traskman-Bendz L, Guillemin GJ, Erhardt S.

Transl Psychiatry. 2016 Aug 2;6(8):e865. doi: 10.1038/tp.2016.133.

45.

Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology.

Coetzee SG, Pierce S, Brundin P, Brundin L, Hazelett DJ, Coetzee GA.

Sci Rep. 2016 Jul 27;6:30509. doi: 10.1038/srep30509.

46.

Nilotinib - Differentiating the Hope from the Hype.

Wyse RK, Brundin P, Sherer TB.

J Parkinsons Dis. 2016 Jul 12;6(3):519-22. doi: 10.3233/JPD-160904.

47.

How strong is the evidence that Parkinson's disease is a prion disorder?

Brundin P, Ma J, Kordower JH.

Curr Opin Neurol. 2016 Aug;29(4):459-66. doi: 10.1097/WCO.0000000000000349. Review.

48.

Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain.

Li W, Englund E, Widner H, Mattsson B, van Westen D, Lätt J, Rehncrona S, Brundin P, Björklund A, Lindvall O, Li JY.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6544-9. doi: 10.1073/pnas.1605245113. Epub 2016 May 2.

49.

Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?

Barker RA, Parmar M, Kirkeby A, Björklund A, Thompson L, Brundin P.

J Parkinsons Dis. 2016;6(1):57-63. doi: 10.3233/JPD-160798.

50.

Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.

Rey NL, George S, Brundin P.

Neuropathol Appl Neurobiol. 2016 Feb;42(1):51-76. doi: 10.1111/nan.12299. Review.

PMID:
26666838

Supplemental Content

Loading ...
Support Center